Comparison of the effectiveness between lafutidine and pantoprazole in uninvestigated dyspepsia.

Phase 4

Completed

• Conditions: Health Condition 1: null- Uninvestigated Dyspepsia

• Registration Number: CTRI/2013/12/004261
• Lead Sponsor: Institute of Postgraduate Medical Education Research

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 122

Inclusion Criteria

•Symptoms of dyspepsia for at least 1 months

•Moderate-to severe symptoms (score >= 4 on the7-point Likert scale for each symptom in global overall symptoms scale).

Exclusion Criteria

•Patient with alarm features (unintentional weight loss, persistent vomiting, dysphagia, hemetemesis, melena, fever, jaundice, or anemia),

•History of serious gastrointestinal disease (including peptic ulcers, malignancy, esophageal dysmotility, a previous endoscopic or radiological diagnosis of GERD and Barrettâ??s esophagus)

•Patients with angina pectoris.

•Patients who show any of the following values at the baseline laboratory tests: Hemoglobin < 9.5 g/dL, total leukocyte count < 3,000/mm3, platelet count < 75,000/mm3, AST and ALT >= 100 IU/L, Creatinine >= 1.5 mg/dl

•Treatment with non-steroidal anti-inflammatory drugs (NSAIDs), H2-blockers, proton pump inhibitors, prokinetic agents, misoprostol or sucralfate 15 days prior to enrollment

•Concomitant serious disease of vital organs such as the liver, kidney, heart or lungs.

•Women who are pregnant, lactating, or not willing to use adequate methods of contraception.

•History of substance abuse.

•Any other condition which can lead the investigators to consider the subject unsuitable for selection.

Study & Design

• Study Type: Interventional
• Study Design: Not specified